IDEXX Laboratories, Inc. — Fiscal 2010 Form 10-K Summary
Business context and reporting period
IDEXX develops diagnostic products and services primarily for companion-animal veterinary practices, livestock and poultry, water testing, dairy testing, and human point-of-care diagnostics. Reported segments were Companion Animal Group (CAG), Water, Livestock and Poultry Diagnostics (LPD), and Other. The filing covers the fiscal year ended December 31, 2010; fourth-quarter data is unaudited.
Financial performance and key metrics
| Metric | 2010 | 2009 | Change |
|---|
| Revenue | $1,103.4 million | $1,031.6 million | +7.0% |
| Gross profit | $578.6 million | $526.3 million | +9.9% |
| Gross margin | 52.4% | 51.0% | +140 bps |
| Operating income | $203.9 million | $176.0 million | +15.9% |
| Operating margin | 18.5% | 17.1% | +140 bps |
| Net income attributable to IDEXX stockholders | $141.3 million | $122.2 million | +15.6% |
| Diluted EPS | $2.37 | $2.01 | +17.9% |
| Net cash from operating activities | $178.8 million | $175.0 million | +$3.9 million |
- CAG generated $905.7 million of revenue, or approximately 82% of consolidated revenue, and grew 7.4% reported and 6.4% organically.
- Water revenue increased 4.5% to $76.5 million; LPD revenue increased 5.1% to $81.2 million; Other revenue increased 5.6% to $40.0 million.
- Reference laboratory services increased 10.5%, and practice information management and digital radiography increased 15.6%. Rapid assay revenue declined 0.4%.
- Sales and marketing expense was $179.6 million, general and administrative expense was $126.5 million, and research and development expense was $68.6 million.
- Interest expense increased to $2.4 million from $1.9 million. The effective tax rate was 30.1%, compared with 30.0% in 2009.
- At December 31, 2010, cash and cash equivalents were $156.9 million, working capital was $175.5 million, total assets were $897.1 million, and stockholders’ equity was $574.3 million.
- Total debt was approximately $133.3 million, including $129.0 million outstanding under the revolving Credit Facility. The company had $70.0 million of remaining borrowing availability and was in compliance with its covenants.
- Cash used in investing activities was $43.2 million, including $38.9 million of capital expenditures and a $4.0 million investment in a veterinary-hospital company. Cash used in financing activities was $86.8 million.
- The company repurchased 2.5 million shares for approximately $143.1 million during 2010. No cash dividends have been paid, and management stated it had no present intention to pay dividends.
Fourth-quarter 2010
| Metric | Q4 2010 | Q4 2009 |
|---|
| Revenue | $283.8 million | $270.3 million |
| Gross profit | $144.8 million | $132.9 million |
| Operating income | $50.8 million | $44.1 million |
| Net income attributable to stockholders | $36.4 million | $31.0 million |
| Diluted EPS | $0.62 | $0.51 |
Material changes versus the prior comparable period
- Revenue growth accelerated from 0.7% in 2009 to 7.0% in 2010, while organic growth was 6.3%. Currency contributed approximately $2.9 million to 2010 revenue.
- Margin expansion was driven primarily by CAG manufacturing and service efficiencies, reference-laboratory volume leverage, lower depreciation on instruments placed at customer sites, and a more favorable product mix.
- Growth benefited from the Catalyst Dx chemistry analyzer and the ProCyte Dx hematology analyzer, launched in the third quarter of 2010. Management expected near-term gross-margin pressure from relatively higher instrument placements as Catalyst Dx penetration continued.
- Rapid assay performance was pressured by lower average selling prices, competitive conditions, and economic weakness affecting U.S. veterinary practices.
- 2010 included $3.0 million of milestone payments related to the 2008 pharmaceutical-product disposition, compared with $2.0 million in 2009. These payments reduced general and administrative expense and were not classified as revenue.
- The company discontinued the Practice Developer customer program and launched Real-Time Care Protocols and Advanced Lab Protocols effective October 1, 2010. Total customer-program revenue reductions increased to $23.9 million from $20.6 million.
- Inventory increased to $127.9 million from $110.4 million, partly reflecting inventory receipts for the ProCyte Dx launch. Inventory was a $19.5 million use of operating cash in 2010.
Guidance, outlook, commentary, risks and unusual items
- Management stated that cash on hand, operating cash flow, and available borrowings were expected to fund operations, capital requirements, and strategic growth for at least the next twelve months. The 2011 capital expenditure plan was approximately $45 million, including $10.5 million for headquarters renovation and expansion.
- Management expected continued pressure on growth from slow economic conditions, fewer veterinary visits, customer price sensitivity, cautious capital purchasing, reduced municipal water studies, and lower government-funded testing.
- Management noted that international sales represented 41% of 2010 revenue. A 10% strengthening of the U.S. dollar was estimated to reduce 2011 operating income by approximately $8 million, excluding certain intercompany and trade-balance effects.
- The company received an FTC subpoena in April 2010 concerning pricing and marketing practices, including possible exclusive dealing or tying arrangements. The U.K. Office of Fair Trading began a related investigation in November 2010. The company was cooperating, had not recorded a loss contingency, and could not predict the outcome.
- The company relies on sole or single-source suppliers for important instruments, consumables, and components; certain supply agreements include minimum purchase obligations.
- Customer concentration is material: Butler Schein Animal Health Supply accounted for 9% of 2010 revenue. Distributor purchasing patterns may not correspond to underlying end-user demand.
- Contractual cash obligations totaled $173.4 million, including $77.0 million of operating leases, $85.0 million of purchase obligations, and $6.7 million of minimum royalty payments. Contingent acquisition-related payments of up to $7.6 million remained outstanding, of which $0.1 million was accrued.
- The company reported no material legal proceedings, no goodwill impairment in 2010, and effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Confirm the sustainability of CAG growth and margin expansion as Catalyst Dx and ProCyte Dx placements mature and consumables become a larger revenue source.
- Assess the effect of economic conditions on veterinary visits, rapid assay utilization, reference-laboratory volumes, and instrument purchases.
- Monitor the FTC and U.K. OFT investigations and any resulting changes to marketing, pricing, or distribution practices.
- Review Credit Facility maturity, covenant compliance, interest-rate exposure, and the $70.0 million remaining availability at year-end.
- Evaluate distributor concentration, inventory levels, customer-program accruals, and the risk that reported revenue reflects distributor purchasing patterns rather than end-user demand.
- Consider foreign-exchange exposure, including the disclosed approximately $8 million operating-income sensitivity to a 10% U.S. dollar strengthening.
- Verify the effect of the $143.1 million share-repurchase program on share count, leverage, liquidity, and future capital allocation.
- Review contingent tax exposures, unrecognized tax benefits, supplier commitments, workers’ compensation claims, and potential milestone payments from divested pharmaceutical assets.
